{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:31:34Z","timestamp":1759530694234,"version":"3.41.2"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2001,2,1]],"date-time":"2001-02-01T00:00:00Z","timestamp":980985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2001,2,1]],"date-time":"2001-02-01T00:00:00Z","timestamp":980985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2001,2]]},"DOI":"10.1023\/a:1005661117739","type":"journal-article","created":{"date-parts":[[2002,12,21]],"date-time":"2002-12-21T18:07:17Z","timestamp":1040494037000},"page":"352-359","source":"Crossref","is-referenced-by-count":8,"title":["Antipyrine Clearance and Metabolite Formation in Primary Biliary Cirrhosis"],"prefix":"10.1007","volume":"46","author":[{"given":"F.","family":"Jorquera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Almar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Linares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. L.","family":"Olc\u00f3z","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Rodrigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gonz\u00e1lez-Gallego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"300306_CR1","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1056\/NEJM199611213352107","volume":"335","author":"MM Kaplan","year":"1996","unstructured":"Kaplan MM: Primary biliary cirrhosis. N Engl J Med 335:1570\u20131580, 1996","journal-title":"N Engl J Med"},{"key":"300306_CR2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1055\/s-2008-1040584","volume":"7","author":"J Ludwig","year":"1987","unstructured":"Ludwig J: New concepts in biliary cirrhosis. Semin Liver Dis 7:293\u2013301, 1987","journal-title":"Semin Liver Dis"},{"key":"300306_CR3","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/jcp.49.7.556","volume":"49","author":"MC Garrido","year":"1996","unstructured":"Garrido MC, Hubscher SG: Accuracy of staging in primary biliary cirrhosis. J Clin Pathol 49:556\u2013559, 1996","journal-title":"J Clin Pathol"},{"key":"300306_CR4","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(97)05419-6","volume":"350","author":"J Neuberger","year":"1997","unstructured":"Neuberger J: Primary biliary cirrhosis. Lancet 350:875\u2013879, 1997","journal-title":"Lancet"},{"key":"300306_CR5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/gut.20.2.137","volume":"20","author":"J Shapiro","year":"1979","unstructured":"Shapiro J, Smith H, Schaffner F: Serum bilirubin: A prognostic factor in primary biliary cirrhosis. Gut 20:137\u2013140, 1979","journal-title":"Gut"},{"key":"300306_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.1840100102","volume":"10","author":"ER Dickson","year":"1989","unstructured":"Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A: Prognosis in primary biliary cirrhosis: Model for decision making. Hepatology 10:1\u20137, 1989","journal-title":"Hepatology"},{"key":"300306_CR7","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S0168-8278(88)80057-6","volume":"6","author":"HE Poulsen","year":"1988","unstructured":"Poulsen HE, Loft S: Antipyrine as a model drug to study hepatic drug-metabolizing capacity. J Hepatol 6: 374\u2013382, 1988","journal-title":"J Hepatol"},{"key":"300306_CR8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2165\/00003088-199120010-00004","volume":"20","author":"JV St Peter","year":"1991","unstructured":"St Peter JV, Awni WM: Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites. Clin Pharmacokinetic 20:50\u201365, 1991","journal-title":"Clin Pharmacokinetic"},{"key":"300306_CR9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/hep.1840100212","volume":"10","author":"SJ Williams","year":"1989","unstructured":"Williams SJ, Farrell GC: Serial antipyrine clearance studies detect altered metabolic function during spontaneous and interferon-induced changes in chronic hepatitis B disease activity. Hepatology 10:192\u2013197, 1989","journal-title":"Hepatology"},{"key":"300306_CR10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2125.1984.tb02533.x","volume":"18","author":"MWE Teunissen","year":"1984","unstructured":"Teunissen MWE, Spoelstra P, Koch CW, Weeda B, Van Duyn W, Jansen AR, Breimer DD: Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis. Br J Clin Pharmacol 18:707\u2013715, 1984","journal-title":"Br J Clin Pharmacol"},{"key":"300306_CR11","first-page":"166","volume":"45","author":"G Wensing","year":"1989","unstructured":"Wensing G, Hoensch HP, Ohnhaus EE: Correlation between microsomal enzyme activity and antipyrine elimination in alcoholic and nonalcoholic with various liver diseases. Clin Pharmacol Ther 45:166\u2013172, 1989","journal-title":"Clin Pharmacol Ther"},{"key":"300306_CR12","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/j.1552-4604.1989.tb03327.x","volume":"29","author":"PJ Pentikainen","year":"1989","unstructured":"Pentikainen PJ, Valisalmi L, Himberg JJ, Crevoisier C: Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol 29:272\u2013277, 1989","journal-title":"J Clin Pharmacol"},{"key":"300306_CR13","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1440-1746.1998.tb00668.x","volume":"13","author":"A Grieco","year":"1998","unstructured":"Grieco A, Catellano R, Mattera A, Marcoccia S, Di Rocco P, Ragazzoni E, Vecchio FM, Gasbarrini G: Antipyrine clearance in chronic and neoplastic liver diseases: A study of 518 patients. J Gastroenterol Hepatol 13:460\u2013466, 1998","journal-title":"J Gastroenterol Hepatol"},{"key":"300306_CR14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0168-8278(95)80254-1","volume":"22","author":"HA Ali","year":"1995","unstructured":"Ali HA, El-Yazigi A, Sieck JE, Ali MA, Raines DA, Saour J, Ernst P, Khan B, Dossing M: Antipyrine clearance and metabolite excretion in patients with chronic hepatitis C. J Hepatol 22:17\u201321, 1995","journal-title":"J Hepatol"},{"key":"300306_CR15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/clpt.1986.138","volume":"40","author":"EA Sotaniemi","year":"1986","unstructured":"Sotaniemi EA, Niemela O, Risteli L, Stenbback F, Pelkonen RO: Fibrotic process and drug metabolism in alcoholic liver disease. Clin Pharmacol Ther 40:46\u201355, 1986","journal-title":"Clin Pharmacol Ther"},{"key":"300306_CR16","doi-asserted-by":"crossref","unstructured":"Grieco A, Castellano R, Matera A, Ragazzoni E, Fontana T, Barone C: Antipyrine metabolism during chemotherapy with 5-fluoracil plus folinic acid in patients with liver metastases from primary colorrectal cancer. Am J Ther 1:255\u2013259","DOI":"10.1097\/00045391-199412000-00002"},{"key":"300306_CR17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/BF00314851","volume":"42","author":"GM Robertz-Vaupel","year":"1992","unstructured":"Robertz-Vaupel GM, Lindecken KD, Edeki T, Funke C, Belwon S, Dengelr HJ: Disposition of antipyrine in patients with extensive metastatic liver disease. Eur J Clin Phramacol 42:465\u2013469, 1992","journal-title":"Eur J Clin Phramacol"},{"key":"300306_CR18","first-page":"1065","volume":"22","author":"S Coverdale","year":"1995","unstructured":"Coverdale S, Byth K, Field J, Liddle C, Lin R, Farrell GC: Antipyrine clearance and response to interferon treatment in patients with chronic active hepatitis C. Hepatology 22:1065\u20131071, 1995","journal-title":"Hepatology"},{"key":"300306_CR19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/hep.510290140","volume":"29","author":"AM Bonnand","year":"1999","unstructured":"Bonnand AM, Heathcote EJ, Lindor KD, Poupon RE: Clinical significance of serum bilirubin levels under ursodeoxycholate acid therapy in patients with primary biliary cirrhosis. Hepatology 29:39\u201343, 1999","journal-title":"Hepatology"},{"key":"300306_CR20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/j.1552-4604.1993.tb03907.x","volume":"33","author":"LL Von Moltke","year":"1993","unstructured":"Von Moltke LL, Abernethy DR, Kaplan MM, Greenblatt DJ: Antipyrine kinetics in patients with primary biliary cirrhosis. J Clin Pharmacol 33:75\u201378, 1993","journal-title":"J Clin Pharmacol"},{"key":"300306_CR21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00432479","volume":"379","author":"J Ludwig","year":"1978","unstructured":"Ludwig J, Dickson ER, McDonald GSA: Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch Pathol Anat 379:103\u2013112, 1978","journal-title":"Virchows Arch Pathol Anat"},{"key":"300306_CR22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000137254","volume":"18","author":"M Danhof","year":"1979","unstructured":"Danhof M, Groot-Van der Vis E, Breimer DD: Assay of antipyrine and its metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man. Pharmacology 18:210\u2013223, 1979","journal-title":"Pharmacology"},{"key":"300306_CR23","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0378-4347(00)80613-1","volume":"433","author":"MA Mikati","year":"1988","unstructured":"Mikati MA, Szabo GK, Pylilo RJ: Improved high-performance liquid chromatographic assay of antipyrine, hydroxymethylantipyrine, 4-hydroxyantipyrine and norantipyrine in urine. J Chromatogr 433:305\u2013311, 1988","journal-title":"J Chromatogr"},{"key":"300306_CR24","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2125.1984.tb02504.x","volume":"18","author":"GC Farrell","year":"1984","unstructured":"Farrell GC, Zaluzny L: Accuracy and clinical utility of simplified tests of antipyrine metabolism. Br J Clin Pharmacol 18:559\u2013565, 1984","journal-title":"Br J Clin Pharmacol"},{"key":"300306_CR25","first-page":"1084","volume":"89","author":"E Christensen","year":"1985","unstructured":"Christensen E, Neuberger J, Crowe JP, Altman DG, Popper H, Portman B, Doniach D, et al: Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Hepatology 89: 1084\u20131091, 1985","journal-title":"Hepatology"},{"key":"300306_CR26","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1159\/000201472","volume":"58","author":"J Von Schonfeld","year":"1997","unstructured":"Von Schonfeld J, Breuer N, Zotz RB, Beste M, Goebell H: Serial quantitative liver function tests in patients with primary biliary cirrhosis. Digestion 58:396\u2013401, 1997","journal-title":"Digestion"},{"key":"300306_CR27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-2362.1974.tb02325.x","volume":"4","author":"PB Andreasen","year":"1974","unstructured":"Andreasen PB, Ranek L, Statland BE, Tygstrup N: Clearance of antipyrine: Dependence on quantitative liver function. Eur J Clin Invest 4:129\u2013134, 1974","journal-title":"Eur J Clin Invest"},{"key":"300306_CR28","first-page":"15","volume":"31","author":"G Wensing","year":"1993","unstructured":"Wensing G, Hoffmmann K, Heidemann HT: Antipyrine elimination in patients with alcoholic and non-alcoholic cirrhosis. Z Gastroenterol 31:15\u201319, 1993","journal-title":"Z Gastroenterol"},{"key":"300306_CR29","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0090-9556(25)07377-5","volume":"24","author":"JE Sharer","year":"1996","unstructured":"Sharer JE, Wrighton SA: Identification of the human hepatic cytochrome P450 involved in the in vitro oxidation of antipyrine. Drug Metab Dispos 24:487\u2013494, 1996","journal-title":"Drug Metab Dispos"},{"key":"300306_CR30","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0009-9236(96)90001-6","volume":"59","author":"G Engel","year":"1996","unstructured":"Engel G, Hofman U, Heidemann H, Cosme J, Eichelbaum M: Antipyrine as a probe for human oxidative metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther 59:613\u2013623, 1996","journal-title":"Clin Pharmacol Ther"},{"key":"300306_CR31","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0009-9236(97)90166-1","volume":"61","author":"EA Sotaniemi","year":"1997","unstructured":"Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M: Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathological conditions. Clin Pharmacol Ther 61:331\u2013339, 1997","journal-title":"Clin Pharmacol Ther"},{"key":"300306_CR32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/gerona\/53A.1.M14","volume":"53","author":"F Jorquera","year":"1998","unstructured":"Jorquera F, Almar MM, Pozuelo M, Sansegundo D, Gonz\u00e1llez-Sastre M, Gonz\u00e1lez-Gallego J: The effect of age and sex on metabolism and urinary excretion of antipyrine. J Gerontol 53:14\u201319, 1998","journal-title":"J Gerontol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1005661117739.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1005661117739\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1005661117739.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T02:55:21Z","timestamp":1752461721000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1005661117739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,2]]}},"alternative-id":["300306"],"URL":"https:\/\/doi.org\/10.1023\/a:1005661117739","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2001,2]]}}}